Updated clinical data from Phase 2 study evaluating oral ridaforolimus presented

[News]

ARIAD Pharmaceuticals, Inc. today announced the presentation of updated clinical data from its Phase 2 study evaluating oral ridaforolimus in combination with trastuzumab (Herceptin®) in patients with resistant, metastatic breast cancer.

More... (http://www.news-medical.net/news/20091215/Updated-clinical-data-from-Phase-2-study-evaluating-oral-ridaforolimus-presented.aspx)